Immunodeficient states and associated rheumatic manifestations

Current Opinion in Rheumatology

Volumn 8, Issue 1, 1996, Pages 52-56

  Stein, C Michael ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; AUTOANTIBODY; CD40 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 2; MACROGOL; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DRUG CONJUGATION; ENZYME DEFICIENCY; HUMAN; HYPERIMMUNOGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; WISKOTT ALDRICH SYNDROME;

EID: 0030045524     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199601000-00010     Document Type: Review

References (26)

1. Report of a WHO Scientific Group: Primary immunodeficiency diseases. Clin Exp Immunol 1995, 99(suppl 1):2-24. A comprehensive update on the classification and pathogenesis of the primary immunodeficiencies. Unfortunately, it is unreferenced.
2. Hirschhorn R: Adenosine deaminase deficiency. Immunodeficiency Rev 1990,2:175-198.
3. Shovlin CL, Simmonds HA, Fairbanks LD, Deacock SJ, Hughes JMB, Lechler RI, Webster AD, Sun X, Webb JC, Southar AK: Adult onset immunodeficiency caused by inherited adenosine deaminase deficiency. J Immunol 1994, 153:2331-2339. The first report of ADA deficiency presenting in adulthood.
4. Cunningham-Rundles C: Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989, 9:22-33.
5. Sneller MC, Strober W, Eisenstein E, Jaffe JS, Cunningham-Rundles C: NIH Conference: new insights into common variable immunodeficiency. Ann Intern Med 1993, 118:720-730.
6. Hauber I, Fischer MB, Maris M, Eibl MM: Reduced IL-2 expression upon antigen stimulation is accompanied by deficient IL-9 gene expression in T cells of patients with CVID. Scand J Immunol 1995, 41:215-219. The authors explore a mechanism for the defective T cell activation in some patients with CVID.
7. Fischer MB, Hauber I, Eggenbauer H, Thon V, Vogel E, Schaffer E, Lokaj J, Litzman J, Wolf HM, Mannhalter JW, Eibl MM: A defect In the early phase of T cell receptor-mediated T cell activation in patients with common variable immunodeficiency. Blood 1994, 84:4234-4241. This study shows that a defect in the early phase of T cell activation is present in some patients with CVID.
8. Laman J, Claasen E, Noelle RJ: Immunodeficiency due to a faulty interaction between T cells and B cells. Curr Opin Immunol 1994, 6:636-641. Useful review highlighting the importance of defects in the interactions between T and B cells in the pathogenesis of immunodeficiency.
9. Farrant J, Spickett G, Matamoros N, Copas D, Hernandez M, North M, Chapel H, Webster AD: Study of B and T cell phenotypes in blood from patients with common variable immunodeficiency (CVID). Immunodeficiency 1994, 5:159-169. The authors demonstrate the importance of T cell regulation of B cell responses.
10. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, Noelle RJ, Aruffo A, Ochs HD: CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA 1994, 91:1099-1103.
11. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Roussel F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 1994, 12:881-922.
12. Conley ME, Larche M, Bonagura VR, Lawton AR, Buckley RH, Fu SM, Coustan-Smith E, Herrod HG, Campana D: Hyper IgM syndrome associated with defective CD40 mediated B cell activation. J Clin Invest 1994, 94:1404-1409. This report shows that in a subset of patients with hyper IgM syndrome, in addition to the defective expression of CD40 ligand, defective signal transduction occurs in T cells expressing CD40 ligand.
13. Foy TM, Masters SR, Noelle RJ: Hyper IgM syndrome: two mutations distinguish HIM. J Clin Invest 1994, 94:1349-1350. This editorial discusses the work of Conley et al. (J Clin Invest 1994, 94:1404-1409) from the perspective of other recent findings and draws attention to the potential importance of the unique nonredundancy of the CD40-CD40 ligand interaction in T cell-dependent humoral immunity.
14. Kwan SP, Hagemann TL, Radtke BE, Blaese RM, Rosen FS: Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene. Proc Natl Acad Sci U S A 1995, 92:4706-4710. Further characterization of the molecular basis of the Wiskott-Aldrich syndrome.
15. Roos D: The genetic basis of chronic granulomatous disease. Immunol Rev 1994, 138:121-157. A useful review of the molecular biology and clinical aspects of chronic granulomatous disease.
16. Cross AR, Heywoth PG, Rae J, Curnutte JT: A variant X-linked chronic granulomatous disease patient (X91+) with partially functional cytochrome b. J Biol Chem 1995, 270:8194-8200. The authors illustrate the heterogeneity of the mutations accounting for CGD.
17. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, Dinauer MC: Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte Superoxide production. Nat Genet 1995, 9:202-209. The authors describe a mouse model of CGD that will be useful for study of this condition.
18. Lee AH, Levinson A, Schumacher HR: Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum 1993, 4:252-264.
19. Lee BW, Yap H: Polyarthritis resembling juvenile rheumatoid arthritis in a girl with chronic granulomatous disease. Arthritis Rheum 1994, 37:773-776. An unusual case, providing a reminder that the association with autoimmune disease is not restricted to the immunodeficiencies associated with decreased immunoglobulins.
20. Mueller BU, Pizzo PA: Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995, 126:1-10. A useful review of the frequency and types of malignancies occurring in immunodeficient patients, particularly children.
21. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS: Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994, 5:91-112. A second review of malignancy complicating immunodeficiencies that reports the data from the Immunodeficiency Cancer Registry. Particularly good in discussing the role of Epstein-Barr virus.
22. Scully RE, Mark EM, McNeely WF, McNeely BU: Case records of the Massachusetts General Hospital: Case 7-1995. N Engl J Med 1995, 332:663-671. This case illustrates the diagnostic difficulties that face clinicians in dealing with immunodeficient patients in whom autoimmune disease, infection, and malignancy may be potential causes of illness.
23. Haeney M: Intravenous Immune globulin in primary immunodeficiency. Clin Exp Immunol 1994, 97(suppl 1):11-15. The author reviews practical aspects of immunoglobulin therapy in immunodeficient patients.
24. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G, et al.: Subcutaneous Immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995, 345:365-369. A report on the efficacy, safety, and cost of home-based subcutaneous immunoglobulin infusions.
25. Hershfield MS. PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 1995, 5:107-112. A review of polyethylene glycol ADA in the management of SCID due to ADA deficiency.
26. Cunningham-Rundles C, Kazbay K, Hassett J, Zhou Z, Mayer L: Enhanced humoral immunity in common variable Immunodeficiency after long-term treatment with polyethylene glycol-conjugated lnterleukin-2. N Engl J Med 1994, 331:918-922. A report of enhanced humoral immunity following treatment of CVID with polyethylene glycol-conjugated interleukin-2.